论文部分内容阅读
目的:采用不同的肾素-血管紧张素系统(RAS)阻断剂干预,观察Zucker肥胖大鼠(ZF鼠)肝脏脂肪含量的变化。方法:12周龄ZF鼠(24只)随机分为4组,分别给予奥美沙坦(ARB组)、替莫普利(ACEI组)、奥美沙坦联合替莫普利(ARB+ACEI组)干预4周,与空白对照组比较,观察ZF鼠肝脏脂肪含量及血脂谱等的变化。结果:干预组ZF鼠血压均较对照组明显下降。3种干预对ZF鼠血胆固醇、三酰甘油水平无明显影响。ARB组治疗后肝脏三酰甘油含量[LTG,(19.9±2.4)mg.g-1 vs.(31.6±9.6)mg.g-1,P<0.05]和肝脏总胆固醇含量[LTC,(1.13±0.07)mg.g-1 vs.(1.52±0.07)mg.g-1,P<0.05]较对照组明显下降,ACEI组较对照组无明显改变,而ARB+ACEI组治疗后LTG及LTC有升高趋势。结论:奥美沙坦显著减少ZF鼠肝脏甘油三酯及总胆固醇含量,而替莫普利及其联合干预无有益影响。
OBJECTIVE: To investigate the changes of liver fat content in Zucker obese rats (ZF mice) with different renin-angiotensin system (RAS) blockers. Methods: Twelve weeks old ZF mice (24 rats) were randomly divided into 4 groups, which were treated with olmesartan (ARB), temocapril (ACEI), olmesartan combined with temocapril (ARB + ACEI) Intervention for 4 weeks, compared with the blank control group, to observe the changes of liver fat content and lipid profile in ZF rats. Results: The blood pressure of ZF rats in intervention group was significantly lower than that in control group. The three kinds of intervention had no significant effect on the level of blood cholesterol and triglyceride in ZF rats. The liver triglyceride levels [LTG (19.9 ± 2.4) mg.g-1 vs. (31.6 ± 9.6) mg.g-1, P <0.05] and liver total cholesterol content [LTC (1.13 ± 0.07) mg.g-1 vs. (1.52 ± 0.07) mg.g-1, P <0.05], while there was no significant difference between the ACEI group and the control group Increase trend. Conclusion: Olmesartan significantly reduces hepatic triglyceride and total cholesterol in ZF mice, but temozolom and its combined intervention have no beneficial effect.